Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)

Neogenomics (NEO) reported Non-Current Deffered Revenue of $1.2 million for Q3 2018, up 85.03% quarter-over-quarter from $648000.0 in Q2 2018.

Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends

Neogenomics has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $1.2 million in Q3 2018.

For the quarter ending Q3 2018, Non-Current Deffered Revenue changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Sep 2018 stood at $1.2 million (changed N/A YoY), and the FY2017 full-year result was $283000.0, changed N/A from the prior year.
Non-Current Deffered Revenue for Q3 2018 stood at $1.2 million, up from $648000.0 in the prior quarter.
The five-year high for Non-Current Deffered Revenue was $1.2 million in Q3 2018, with the low at $283000.0 in Q4 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Waters	29,149.49 Bn	29,149.03 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	174.37 Bn	171.12 Bn	7.74 Bn	-
3	Danaher	127.33 Bn	121.64 Bn	3.59 Bn	-
4	Idexx Laboratories	44.68 Bn	44.48 Bn	722.74 Mn	32.31 Mn
5	Agilent Technologies	36.54 Bn	34.74 Bn	990.00 Mn	-
6	Iqvia Holdings	30.51 Bn	28.53 Bn	1.36 Bn	-
7	Natera	30.00 Bn	28.90 Bn	696.04 Mn	17.00 Mn
8	Illumina	24.61 Bn	23.45 Bn	721.00 Mn	-
9	Mettler Toledo International	22.91 Bn	22.85 Bn	555.82 Mn	-
10	Neogenomics	1.44 Bn	1.29 Bn	80.86 Mn	-

Download Data